tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

YMAB Stock Latest News

Promising R&D Developments and New Radiohapten Propel Y-Mabs Therapeutics to a Buy Rating
RatingsPromising R&D Developments and New Radiohapten Propel Y-Mabs Therapeutics to a Buy Rating
1M ago
YMAB
Optimistic Outlook on Y-mAbs Therapeutics’ GD2-SADA Platform Despite Developmental Delays
PremiumRatings
Optimistic Outlook on Y-mAbs Therapeutics’ GD2-SADA Platform Despite Developmental Delays
1M ago
YMAB
Y-mAbs Therapeutics price target lowered to $15 from $20 at Oppenheimer
PremiumThe Fly
Y-mAbs Therapeutics price target lowered to $15 from $20 at Oppenheimer
1M ago
YMAB
Y-Mabs Therapeutics: Buy Rating Affirmed on Promising SADA Program Advancements and Market Expansion Potential
PremiumRatings
Y-Mabs Therapeutics: Buy Rating Affirmed on Promising SADA Program Advancements and Market Expansion Potential
1M ago
YMAB
Prolonged Development Timelines and Limited Near-Term Catalysts Lead to Sell Rating for Y-Mabs Therapeutics
PremiumRatings
Prolonged Development Timelines and Limited Near-Term Catalysts Lead to Sell Rating for Y-Mabs Therapeutics
1M ago
YMAB
Cautious Outlook on Y-Mabs Therapeutics Due to Delayed Milestones and Early-Stage Pipeline
PremiumRatingsCautious Outlook on Y-Mabs Therapeutics Due to Delayed Milestones and Early-Stage Pipeline
1M ago
YMAB
Y-Mabs Therapeutics Updates on Radiopharmaceutical Progress
Premium
Company Announcements
Y-Mabs Therapeutics Updates on Radiopharmaceutical Progress
1M ago
8K
YMAB
Y-mAbs Therapeutics price target lowered to $11 from $12 at H.C. Wainwright
Premium
The Fly
Y-mAbs Therapeutics price target lowered to $11 from $12 at H.C. Wainwright
2M ago
YMAB
Y-mAbs Therapeutics’ Earnings Call: Mixed Sentiment and Future Outlook
PremiumCompany Announcements
Y-mAbs Therapeutics’ Earnings Call: Mixed Sentiment and Future Outlook
2M ago
YMAB
Y-mAbs Therapeutics price target lowered to $20 from $21 at Oppenheimer
PremiumThe Fly
Y-mAbs Therapeutics price target lowered to $20 from $21 at Oppenheimer
2M ago
YMAB
Positive Outlook for Y-Mabs Therapeutics Amid Strategic Developments and NCCN Inclusion
PremiumRatings
Positive Outlook for Y-Mabs Therapeutics Amid Strategic Developments and NCCN Inclusion
2M ago
YMAB
Y-mAbs Therapeutics Reports Q1 2025 Financial Results
PremiumCompany Announcements
Y-mAbs Therapeutics Reports Q1 2025 Financial Results
2M ago
YMAB
Cautious Outlook on Y-Mabs Therapeutics Amidst Competitive and Enrollment Challenges
PremiumRatingsCautious Outlook on Y-Mabs Therapeutics Amidst Competitive and Enrollment Challenges
2M ago
YMAB
UnitedHealth suspends outlook, Under Armour reports Q4 beat; Morning Buzz
Premium
The Fly
UnitedHealth suspends outlook, Under Armour reports Q4 beat; Morning Buzz
2M ago
BA
JD
Morning Movers: UnitedHealth sinks following CEO exit and outlook suspension
Premium
The Fly
Morning Movers: UnitedHealth sinks following CEO exit and outlook suspension
2M ago
JD
UA
Y-mAbs Therapeutics reports Q1 EPS (12c), consensus (20c)
PremiumThe Fly
Y-mAbs Therapeutics reports Q1 EPS (12c), consensus (20c)
2M ago
YMAB
Y-mAbs Therapeutics sees 2025 revenue $75M-$90M, consensus $82.49M
PremiumThe Fly
Y-mAbs Therapeutics sees 2025 revenue $75M-$90M, consensus $82.49M
2M ago
YMAB
YMAB Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
YMAB Upcoming Earnings Report: What to Expect?
2M ago
YMAB
Y-mAbs Therapeutics announces naxitamab-gqgk recommended by NCCN
PremiumThe Fly
Y-mAbs Therapeutics announces naxitamab-gqgk recommended by NCCN
2M ago
YMAB
Y-mAbs Therapeutics announces presentation of PK data of CD38-SADA
PremiumThe FlyY-mAbs Therapeutics announces presentation of PK data of CD38-SADA
2M ago
YMAB
Y-mAbs announces first patient dosed in Phase 1 trial of CD38-SADA PRIT platform
Premium
The Fly
Y-mAbs announces first patient dosed in Phase 1 trial of CD38-SADA PRIT platform
2M ago
YMAB
Y-mAbs Therapeutics downgraded to Underperform from Neutral at BofA
Premium
The Fly
Y-mAbs Therapeutics downgraded to Underperform from Neutral at BofA
2M ago
YMAB

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >